Lilly goes cellular for $34m
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
Nkarta goes back to basics
After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.
ADA 2023 – Vertex raises hopes of type 1 diabetes cure
But it still has a long way to go with its islet cell therapies.
Cartesian maps the path for an autoimmune disease cell therapy
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
Car-T beyond cancer? Novartis and others say yes
Putting Car-T therapy to work in autoimmune diseases has caught the attention of several biotech and big pharma groups.
Delays fail to Quell Treg interest
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
The quiet resurgence of Cellular Biomedicine
Cellular Biomedicine Group has had a rollercoaster existence, and emerged from obscurity this week with a $245m injection from J&J.
PD-1 versus Car-T: stop making sense
T-cell exhaustion, a frequently cited reason for Car-T relapse, might be reversed by PD-(L)1 blockade; but is exhaustion really the problem?
